Comparison · NCT01769196-25ec9d40
Simtuzumab vs Simtuzumab Placebo: Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Simtuzumab vs Simtuzumab Placebo: Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations. Trial comparisons, record NCT01769196-25ec9d40. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01769196-25ec9d40
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0505 | 0.0218 | 0.113 | wilson | |
| Risk in group 2 | 0.0595 | 0.0257 | 0.132 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00902 | -0.0869 | 0.0619 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.848 | 0.254 | 2.83 | log | |
| Odds ratio, group 1 over group 2 | 0.84 | 0.235 | 3.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Simtuzumab than on Simtuzumab Placebo | 111 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Simtuzumab | Simtuzumab 125 mg/mL administered subcutaneously once a week | 5 | 99 | OG000 |
| Group 2 | Simtuzumab Placebo | Simtuzumab placebo administered subcutaneously once a week | 5 | 84 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations
- Description
- Time frame
- Up to 148 weeks
- Population
- Participants in the ITT Analysis Set with adjudicated respiratory hospitalizations were analyzed.
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- NCT number
- NCT01769196
- Phases
- PHASE2
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2017-04-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01769196?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01769196-25ec9d40